Please login to the form below

Not currently logged in
Email:
Password:

Industry contests FDA ruling

In March, the FDA sent letters to 14 major pharmaceutical companies stating that the companies' search advertisements had to start including risk information about each drug

In March, the Food and Drug Administration (FDA) sent letters to 14 major pharmaceutical companies, including Eli Lilly, GlaxoSmithKline, Merck and Pfizer, stating that the companies' search advertisements — the short text ads that run beside Google results — had to start including risk information about each drug, or be rewritten or removed. According to a report in the New York Times, the letters said ads for widely prescribed drugs, including Celebrex, Propecia and Yaz, did not include the paragraphs of precautions the agency required.

Until the letters went out, pharma companies believed they were in compliance with Internet search ad regulations as long as the companies provided complete risk information within one click of the ad. The letters, however, made clear that such ads were not in compliance.

Executives from the companies do not believe that it is possible to include all required information in the 95 characters that Google allows for such ads. They also have expressed their concern that attempting to fit such risk information into the ads has led to the ads becoming even more confusing than before. Companies are concerned that the FDA will force them to adhere to standards similar to those established for magazines and television, instead of developing new standards that reflect the evolution of Internet advertising.

20th April 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics